...
oric-img

Oric Pharmaceuticals Inc, Common Stock

ORIC

GSN

$9.6

-$0.57

(-5.6%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$703.55M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
282.03K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.12
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.33 L
$16.65 H
$9.6

About Oric Pharmaceuticals Inc, Common Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameORICSectorS&P500
1-Week Return-2.04%0.67%0.49%
1-Month Return1.27%0.26%5.96%
3-Month Return-4.67%-6.21%9.35%
6-Month Return9.34%1.69%14.4%
1-Year Return13.61%11.41%32.23%
3-Year Return-31.96%12.87%33.15%
5-Year Return-62.75%48.89%95.23%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue1.00M970.00K897.00K966.00K1.03M[{"date":"2019-12-31","value":96.9,"profit":true},{"date":"2020-12-31","value":93.99,"profit":true},{"date":"2021-12-31","value":86.92,"profit":true},{"date":"2022-12-31","value":93.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(1.00M)(970.00K)(897.00K)(966.00K)(1.03M)[{"date":"2019-12-31","value":-100000000,"profit":false},{"date":"2020-12-31","value":-97000000,"profit":false},{"date":"2021-12-31","value":-89700000,"profit":false},{"date":"2022-12-31","value":-96600000,"profit":false},{"date":"2023-12-31","value":-103200000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses28.57M49.34M78.87M86.77M110.78M[{"date":"2019-12-31","value":25.79,"profit":true},{"date":"2020-12-31","value":44.54,"profit":true},{"date":"2021-12-31","value":71.2,"profit":true},{"date":"2022-12-31","value":78.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(28.57M)(74.19M)(78.87M)(91.77M)(110.78M)[{"date":"2019-12-31","value":-2856900000,"profit":false},{"date":"2020-12-31","value":-7418600000,"profit":false},{"date":"2021-12-31","value":-7887100000,"profit":false},{"date":"2022-12-31","value":-9176700000,"profit":false},{"date":"2023-12-31","value":-11078000000,"profit":false}]
Total Non-Operating Income/Expense3.08M789.00K297.00K5.29M-[{"date":"2019-12-31","value":58.28,"profit":true},{"date":"2020-12-31","value":14.91,"profit":true},{"date":"2021-12-31","value":5.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(26.88M)(73.70M)(78.72M)(89.12M)(100.70M)[{"date":"2019-12-31","value":-2688300000,"profit":false},{"date":"2020-12-31","value":-7370300000,"profit":false},{"date":"2021-12-31","value":-7871500000,"profit":false},{"date":"2022-12-31","value":-8912200000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false}]
Income Taxes(1.40M)23.57M(1.04M)2.35M-[{"date":"2019-12-31","value":-5.93,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-4.4,"profit":false},{"date":"2022-12-31","value":9.99,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(25.49M)(97.27M)(77.68M)(91.48M)-[{"date":"2019-12-31","value":-2548600000,"profit":false},{"date":"2020-12-31","value":-9727000000,"profit":false},{"date":"2021-12-31","value":-7767700000,"profit":false},{"date":"2022-12-31","value":-9147700000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(26.88M)(73.70M)(78.72M)(89.12M)(100.70M)[{"date":"2019-12-31","value":-2688300000,"profit":false},{"date":"2020-12-31","value":-7370300000,"profit":false},{"date":"2021-12-31","value":-7871500000,"profit":false},{"date":"2022-12-31","value":-8912200000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(25.49M)(97.27M)(77.68M)(91.48M)(100.70M)[{"date":"2019-12-31","value":-2548600000,"profit":false},{"date":"2020-12-31","value":-9727000000,"profit":false},{"date":"2021-12-31","value":-7767700000,"profit":false},{"date":"2022-12-31","value":-9147700000,"profit":false},{"date":"2023-12-31","value":-10069700000,"profit":false}]
EPS (Diluted)(0.08)(6.22)(2.07)(2.25)(1.96)[{"date":"2019-12-31","value":-8,"profit":false},{"date":"2020-12-31","value":-622,"profit":false},{"date":"2021-12-31","value":-207,"profit":false},{"date":"2022-12-31","value":-225,"profit":false},{"date":"2023-12-31","value":-196,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ORIC
Cash Ratio 12.82
Current Ratio 13.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ORIC
ROA (LTM) -29.22%
ROE (LTM) -45.98%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ORIC
Debt Ratio Lower is generally better. Negative is bad. 0.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.91

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ORIC
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.55
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.13

FAQs

What is Oric Pharmaceuticals Inc share price today?

Oric Pharmaceuticals Inc (ORIC) share price today is $9.6

Can Indians buy Oric Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Oric Pharmaceuticals Inc (ORIC) on Vested. To buy Oric Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ORIC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Oric Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Oric Pharmaceuticals Inc (ORIC) via the Vested app. You can start investing in Oric Pharmaceuticals Inc (ORIC) with a minimum investment of $1.

How to invest in Oric Pharmaceuticals Inc shares from India?

You can invest in shares of Oric Pharmaceuticals Inc (ORIC) via Vested in three simple steps:

  • Click on Sign Up or Invest in ORIC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Oric Pharmaceuticals Inc shares
What is Oric Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Oric Pharmaceuticals Inc (ORIC) is $16.65. The 52-week low price of Oric Pharmaceuticals Inc (ORIC) is $6.33.

What is Oric Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Oric Pharmaceuticals Inc (ORIC) is

What is Oric Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Oric Pharmaceuticals Inc (ORIC) is 2.55

What is Oric Pharmaceuticals Inc dividend yield?

The dividend yield of Oric Pharmaceuticals Inc (ORIC) is 0.00%

What is the Market Cap of Oric Pharmaceuticals Inc?

The market capitalization of Oric Pharmaceuticals Inc (ORIC) is $703.55M

What is Oric Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Oric Pharmaceuticals Inc is ORIC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top